Results 181 to 190 of about 34,322 (240)

Sex Differences in Treatment Expectations, Satisfaction and Tolerance After Switching to CT-P17, an Adalimumab Biosimilar: A Post Hoc Analysis of the YU-MATTER Study. [PDF]

Rheumatol Ther
Gossec L, Bouguen G, Dellal A, Foulley L, Habauzit C, Benkhalifa S, Marotte H.   +6 more
europepmc   +1 more source

Preserving Valued Activities in Life for Adults With Rheumatoid Arthritis: Development and Pre‐Testing Refinement of the PREVAIL Model of Care

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Objective Rehabilitation is rarely integrated into routine rheumatology care, despite high rates of functional limitation in adults with rheumatoid arthritis (RA). The Preserving Valued Activities in Life (PREVAIL) model of care proposes a function‐focused screening survey administered during routine rheumatology visits to guide referrals to ...
Louise M. Thoma, Joel R. Thompson, Jason Sharpe, Beth Jonas, Patti Katz, Kelli Allen   +5 more
wiley   +1 more source

Splenic Tuberculosis in a Patient With Crohn's Disease Receiving Anti-tumor Necrosis Factor-α (TNF-α) Therapy: A Case Report. [PDF]

Cureus
Boucaid A, Tiresse N, Zegmout A, Souhi H, Rhorfi I, Elouazzani H.   +5 more
europepmc   +1 more source

Treatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First‐Line Therapy

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1789-1797, August 2026.
Objective Treatment of childhood chronic idiopathic uveitis (cCIU) is predominantly based on studies in juvenile idiopathic arthritis–associated uveitis and expert opinion. Our aim was to report the treatment outcomes of our cohort of cCIU. Methods Retrospective multicenter study involving the rheumatology and ophthalmology units at Florence, Italy ...
Ilaria Maccora, Catherine Guly, Cinzia de Libero, Giulia Carreras, Athimalaipet V. Ramanan, Gabriele Simonini   +5 more
wiley   +1 more source

Case Report: Rapid improvement with upadacitinib in a case of paradoxical skin lesions associated with SAPHO syndrome. [PDF]

Front Immunol
Du J, Gao Y, Geng S, Li C, Shang S.
europepmc   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1674-1686, August 2026.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Testicular seminoma in patients receiving adalimumab: two case reports. [PDF]

An Bras Dermatol
Vilela BF, Martins IA, Cunha N, Cabete J.   +3 more
europepmc   +1 more source

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 510-519, August 2026.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

Roadmap for the accelerated development and clinical translation of fluorescent tracers: Adalimumab-680LT as a proof of concept. [PDF]

Int J Pharm X
Huizinga HK, van Dijken RJ, Gareb B, Dekkers BGJ, van Zanten J, Westra HH, Koopmans P, Nagengast WB, Lub-de Hooge MN.   +8 more
europepmc   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source